Hims vs Roman vs Maximus TRT Comparison (2026): The One Difference Nobody Mentions

Executive Summary

Most men researching 'Hims vs Roman vs Maximus TRT' believe they are comparing three equivalent testosterone replacement therapy providers. They are not. The most important fact about this comparison is one that almost none of the ranking articles mention: Hims does not currently offer traditional TRT. Hims prescribes enclomiphene — a selective estrogen receptor modulator (SERM) that stimulates your own pituitary-testicular axis to produce more testosterone — not exogenous testosterone injections or creams. That is a fundamentally different mechanism, a different candidate profile, a different lab picture, and in many cases, a different outcome.

Roman and Maximus are both legitimate exogenous TRT platforms, but they serve different profiles. Roman is a general consumer telehealth brand with a template-driven clinical model. Maximus is performance-focused, prescribes testosterone cypionate plus optional hCG for fertility preservation, uses an at-home lab model that drives higher monitoring compliance, and attracts men who want to optimize rather than just normalize. If you are trying to figure out which platform is right for you, the most important question is not which has the best app or the lowest headline price — it is whether you have primary or secondary hypogonadism, and whether fertility preservation matters to your situation. Those two variables determine which platform is clinically appropriate before cost enters the equation.

This comparison covers what each platform actually prescribes, what the monitoring looks like, what the honest all-in cost is, and which clinical profiles each one is designed for. Use it alongside compare TRT providers for side-by-side detail. If you are still deciding whether you need TRT at all, read TRT vs natural testosterone boosting first.

At-a-Glance Comparison

All-in monthly estimates include medication and prorated lab costs at standard monitoring frequency. Hims prescribes enclomiphene (SERM), NOT exogenous testosterone — the most critical distinction in this comparison. Updated March 2026.

Hims: What It Actually Prescribes — and Why That Matters

Hims is the largest men's health telehealth brand by consumer awareness, which is why so many men start their TRT research here. The confusion arises because Hims markets itself in the testosterone space extensively, which leads men to assume it prescribes testosterone. As of early 2026, it does not. Hims prescribes enclomiphene — a third-generation selective estrogen receptor modulator (SERM) that blocks estrogen receptors in the hypothalamus and pituitary, which signals those organs to increase LH and FSH output, which in turn tells the testes to produce more testosterone. The result is higher endogenous testosterone without suppressing the HPT axis. Hims has announced plans to introduce injectable and oral testosterone (Kyzatrex, an FDA-approved oral capsule) in 2026, but those were not available at time of publication. Buyers searching for hims vs roman vs maximus trt comparison usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Enclomiphene is a clinically legitimate treatment — it is not a supplement or a workaround. For men with secondary hypogonadism (where the testes can produce testosterone normally but are not being stimulated adequately by the pituitary), enclomiphene can raise testosterone levels meaningfully while preserving the HPT axis, maintaining sperm production, and keeping fertility intact. Clinical studies show enclomiphene can raise total testosterone by 100–200 ng/dL in secondary hypogonadal men over 8–16 weeks. That is a real effect — smaller than exogenous TRT but potentially adequate for men in the 280–400 ng/dL range whose primary concern is fertility or avoiding suppression. For men with primary hypogonadism — where the testes themselves cannot produce adequate testosterone regardless of LH/FSH signaling — enclomiphene does not work, because the downstream production capacity is absent. This is not a fringe edge case: primary hypogonadism accounts for roughly 30–40% of clinically confirmed hypogonadism cases. For these men, exogenous TRT is the only effective pathway. If your LH and FSH are already elevated on your labs and your testosterone is still low, that is a primary hypogonadism picture — Hims is not the right platform. See how to read your testosterone lab results to understand where your LH/FSH picture places you. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The most common error in this comparison is men with primary hypogonadism enrolling with Hims because of brand familiarity, spending months on enclomiphene, and not seeing adequate results — not because the platform failed, but because the treatment approach was clinically wrong for their diagnosis. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Roman (Ro): Consumer TRT at Scale — Convenience First, Depth Second

Roman and Hims are under the same parent company (Hims & Hers Health, Inc.), but they have different product strategies. Roman does prescribe exogenous testosterone — including testosterone cypionate injections and topical testosterone cream — which makes it a legitimate TRT comparison point alongside Maximus for men who need exogenous T. Roman's model is asynchronous-first telehealth: you complete an intake form, upload or order labs, and receive a clinician review within 24–48 hours. The onboarding experience is polished. The ongoing clinical depth is template-driven rather than individually optimized. Buyers searching for hims vs roman vs maximus trt comparison usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Roman's TRT offering works adequately for men with straightforward confirmed hypogonadism — clear low T on a full panel, no fertility concerns, no complex protocol history, willing to accept a template approach. Lab costs are typically paid separately ($75–$150 per lab draw at a partner lab center), which brings the realistic all-in estimate to approximately $150–$260/month depending on medication dose and testing frequency. The model's structural limitation is what happens after onboarding: estradiol management, protocol adjustments, hCG prescribing, and troubleshooting for non-responders are areas where Roman's asynchronous template model consistently underperforms compared to dedicated TRT-specialist practices. A well-documented pattern in TRT forums is men starting with Roman's consumer convenience and migrating to Maximus or a specialist clinic within 6–12 months when a protocol problem emerges that requires the kind of individualized management Roman is not designed to provide. If your case is simple and you want low-friction onboarding, Roman works. If you have any complexity — elevated estradiol, fertility concerns, history of protocol issues — budget for an upgrade path at some point. Reference how to get prescribed testosterone online for what a legitimate telehealth qualification process should look like at any provider. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Roman's polished onboarding creates an accurate impression of consumer quality but an inaccurate impression of ongoing clinical depth. The mismatch is typically invisible during the first 2 months and becomes apparent at the first protocol adjustment or estradiol issue. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Maximus Tribe: Performance-Focused TRT with the Best Mid-Tier Monitoring Model

Maximus Tribe is the most consistently recommended platform in the mid-tier across independent TRT communities (r/Testosterone, Testosterone Nation, and longevity optimization forums). Its positioning is genuinely different from Roman's: where Roman is consumer convenience, Maximus is performance and optimization. The base protocol is testosterone cypionate with at-home finger-stick lab kits — a model that drives meaningfully higher monitoring compliance than programs where patients must schedule and pay separately for in-person lab center draws. The difference matters: higher compliance means better protocol optimization data, faster dose adjustments, and fewer months on an inadequate or drifting protocol. Buyers searching for hims vs roman vs maximus trt comparison usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Maximus' at-home lab model starts around $149/panel for a comprehensive hormone + CBC panel, and quarterly testing is included in the program structure with explicit compliance prompts — creating a monitoring feedback loop that budget-tier programs don't replicate at this price point. The base testosterone protocol runs approximately $150–$200/month, and the clinic is willing to add hCG for fertility preservation alongside exogenous testosterone — a service most consumer platforms don't offer at this price. The all-in estimate with at-home labs prorated runs approximately $150–$260/month. For men comparing Maximus versus Defy Medical, the trade-off is depth versus cost: Maximus delivers approximately 75–80% of the monitoring value for 50–60% of the cost for non-complex cases. Where Maximus underperforms is for men who need complex adjunct management — simultaneous TRT, peptides, GLP-1 optimization, and thyroid work — or who have a protocol failure history requiring specialist troubleshooting. For those situations, a clinic like Defy Medical's assigned-clinician model is more defensible. See TRT side effects for the range of protocol issues that differentiate mid-tier and specialist management. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: At-home finger-stick testing has real technical limitations for certain markers. Advanced biomarkers — sensitive estradiol specifically, prolactin, and full CBC with differential — may require supplemental in-clinic lab draws for complex presentations. Maximus works for typical cases; it is not the right platform for outlier presentations. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Decision Framework: Primary vs Secondary Hypogonadism Is the Fork in the Road

Most men who choose the wrong platform from this comparison did not choose based on bad information about the platforms — they chose before understanding their own clinical picture. The single most important variable in the Hims vs Roman vs Maximus decision is whether you have primary or secondary hypogonadism. That determination requires knowing your LH and FSH levels, not just your total testosterone, and most men never get those tested or know what the results mean. Buyers searching for hims vs roman vs maximus trt comparison usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Here is the decision logic. First, if you do not have lab results showing LH and FSH, do not pick a platform yet. Order a full baseline panel through any of these providers or a direct lab service. Your LH/FSH picture determines your viable options. If your LH and FSH are elevated (above range) and your testosterone is low, that is primary hypogonadism — the testes are not responding despite adequate pituitary signaling. Enclomiphene (Hims) will not help you; you need exogenous TRT. Roman or Maximus are your options. If your LH and FSH are low or normal and your testosterone is low, that is secondary hypogonadism — your pituitary is underdriving the system. Enclomiphene (Hims) has a real role here, especially if fertility is a concern. Exogenous TRT (Roman, Maximus) will also work, but will suppress the axis and end natural testosterone and sperm production while you are on it. Second variable: fertility. If fertility preservation matters — actively trying to conceive, or wanting to preserve the option — Hims' enclomiphene model or Maximus' TRT + hCG model are the two paths. Roman's consumer TRT without hCG suppresses fertility for the duration of treatment. Third: case complexity. If you have a prior protocol history, estradiol sensitivity, or need simultaneous management of multiple hormonal systems, go to a specialist practice first rather than discovering the mid-tier mismatch later. See TRT vs natural testosterone boosting for the full diagnostic framework, and use compare TRT providers to evaluate any platform with a side-by-side view. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Men who skip the LH/FSH step are making a platform choice without the most important diagnostic variable. This is the number one driver of mismatched enrollments in all three platforms. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Total Cost Comparison: What You Actually Pay Over Six Months

Published pricing across all three platforms is systematically misleading because it omits labs, follow-up consultations, and likely add-ons. The only number that matters for budgeting is the total six-month cost including medication, required labs at monitoring frequency, and standard consultations. Built-in labs models (Maximus) and patient-pays-separately models (Roman, some Hims packages) produce very different cash-flow structures even when the base subscription prices overlap. Buyers searching for hims vs roman vs maximus trt comparison usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Six-month cost models as of March 2026. Hims enclomiphene: $99–$175/month medication subscription plus two baseline labs and one follow-up draw ($75–$150 each, typically required quarterly) = approximately $850–$1,400 for six months all-in, depending on package and lab frequency. If Hims' injectable or oral testosterone options have launched in your state, add $50–$100/month to the medication line. Roman TRT: $129–$199/month medication plus quarterly lab draws at patient cost ($75–$150 each) = approximately $950–$1,600 for six months. Maximus TRT: $150–$200/month base subscription plus at-home lab kit ($149 per panel quarterly, prorated to ~$50/month) = approximately $1,200–$1,500 for six months — the lab cost is higher per month but eliminates the friction of scheduling and payment at a lab center, which is why compliance is better. The underlying insight: Maximus costs slightly more than Roman on a six-month basis but delivers demonstrably higher monitoring value through the at-home model. Hims enclomiphene is the lowest true all-in cost for secondary hypogonadism candidates. See how much does TRT cost for the full cost breakdown across all online and offline TRT provider tiers. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Sticker-price optimization is the most expensive mistake in TRT provider selection. Men who choose the lowest subscription and skip labs end up either managing an unmonitored protocol — a real health risk — or scrambling to schedule separate lab draws that erode the cost advantage they optimized for. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

Your LH and FSH numbers — not your total testosterone alone — determine which of these platforms is clinically appropriate for your situation. Get the full panel first. Then use the decision framework above to match the platform to your diagnosis, fertility priorities, and case complexity. Use our provider comparison tool to evaluate any specific clinic with a side-by-side view.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

Does Hims offer TRT (testosterone replacement therapy)?

Not as of early 2026. Hims prescribes enclomiphene — a SERM that stimulates your body's natural testosterone production — not exogenous testosterone injections or creams. Hims has announced plans to introduce injectable testosterone and oral testosterone (Kyzatrex) in 2026, but availability is state-dependent and was not universal at time of publication. If you specifically need exogenous TRT, Roman or Maximus are the relevant options in this comparison.

What is enclomiphene and how is it different from TRT?

Enclomiphene is a third-generation SERM (selective estrogen receptor modulator) that stimulates the hypothalamus and pituitary to increase LH and FSH output, which signals the testes to produce more testosterone naturally. Unlike exogenous TRT, enclomiphene preserves the HPT axis and maintains fertility. The trade-off: it only works for secondary hypogonadism (where the pituitary-testicular axis is functional), it cannot produce the testosterone increase of exogenous TRT in men with primary hypogonadism, and results are typically more modest (100–200 ng/dL increase) than injection-based TRT.

Which is better: Hims vs Maximus for low testosterone?

They serve different clinical profiles. Hims (enclomiphene) is appropriate for secondary hypogonadism — where LH and FSH are low or normal and the pituitary-testicular axis can be stimulated to produce more T. Maximus (exogenous TRT) is appropriate for men who need exogenous testosterone regardless of axis function. If fertility preservation matters and you have secondary hypogonadism, Hims' enclomiphene model has a real role. If you need straightforward TRT with strong monitoring and optional hCG, Maximus is the better comparison point. The first step is knowing your LH and FSH.

Is Roman or Maximus better for TRT in 2026?

For most men who want exogenous TRT at a mid-market price, Maximus is the more consistently recommended option. The at-home lab model drives higher monitoring compliance, the base protocol is performance-focused rather than template-driven, and the option to add hCG for fertility preservation is a meaningful advantage Roman's consumer model typically doesn't match. Roman works for simple cases with low-friction onboarding priorities; Maximus is the better choice for men who want to actively engage with protocol optimization and monitoring.

How do I know if I have primary or secondary hypogonadism?

You need LH and FSH on your lab panel — not just total testosterone. If LH and FSH are elevated and your testosterone is still low, your pituitary is signaling correctly but your testes are not responding — that is primary hypogonadism, and enclomiphene will not work. If LH and FSH are low or normal with low testosterone, the pituitary is underdriving the system — that is secondary hypogonadism, where enclomiphene has clinical utility. This is the most important lab distinction in the entire Hims vs Roman vs Maximus comparison.

Does Maximus preserve fertility while on TRT?

Maximus offers hCG as an add-on to exogenous TRT protocols — hCG stimulates the testes directly via an LH-mimicking mechanism, helping maintain testicular size and sperm production while on exogenous testosterone. This is a meaningful advantage for men who want to maintain fertility optionality while on TRT. Roman's consumer model does not routinely offer hCG at this price point. Hims' enclomiphene model preserves fertility natively by maintaining the HPT axis without suppression.

What labs should I get before choosing between these three platforms?

At minimum: total testosterone, free testosterone or SHBG (to calculate free T), LH, FSH, sensitive estradiol (E2), CBC (for hematocrit), and comprehensive metabolic panel. Any legitimate platform should require this panel before prescribing. The LH and FSH values are the diagnostic key that determines whether enclomiphene (Hims) is appropriate or whether you need exogenous TRT (Roman, Maximus). If a platform is willing to prescribe without LH and FSH, that is a red flag.

How much does Hims vs Roman vs Maximus actually cost per month?

True all-in monthly estimates including labs: Hims enclomiphene approximately $115–$175/month (medication + quarterly labs prorated); Roman TRT approximately $150–$260/month (medication + labs paid separately); Maximus TRT approximately $175–$260/month (medication + at-home lab kit prorated). The Maximus total is slightly higher than Roman but includes the at-home lab model that eliminates scheduling friction — the net monitoring compliance advantage typically justifies the premium for men who will actually use it.

Can I switch from Hims enclomiphene to TRT with another provider if it is not working?

Yes. If you started with Hims' enclomiphene protocol and are not seeing adequate results after 8–12 weeks on a therapeutic dose, transitioning to exogenous TRT with Roman or Maximus is a reasonable next step. Keep your baseline lab results and any follow-up labs from your Hims protocol — they provide valuable context for your new provider's onboarding. The LH/FSH pattern in your labs will confirm whether the enclomiphene mismatch was diagnostic (primary hypogonadism) or insufficient response at secondary hypogonadism.

What is the biggest mistake men make when choosing between Hims, Roman, and Maximus?

Choosing based on brand familiarity or marketing exposure rather than their own lab results. Men with primary hypogonadism enroll with Hims, spend months on enclomiphene, and see inadequate results — not because Hims failed, but because the treatment mechanism cannot work for their diagnosis. Men with secondary hypogonadism and fertility concerns enroll with Roman and discover too late that hCG is not part of the standard protocol. Both outcomes are predictable and avoidable if you check LH and FSH before choosing a platform.